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Potential Use of a Terbium - Transferrin Complex as a Label in an 
lmmunoassay for Gentamicin 
Nichola J. Wilmott, James N. Miller and Julian F. Tyson 
Chemistry Department, Loughborough University of Technology, Loughborough, Leicestershire, 
LEI I 3TU, UK 
A study has been made of the potential use of a terbium - transferrin complex as a non-isotopic label in the 
immunoassay determination of the antibiotic gentamicin. The fluorescence properties of the complex have 
been characterised. The labelled gentamicin was formed using a controlled carbodiimide reaction, conditions 
being chosen to produce a gentamicin-bound complex containing the correct amount of gentamicin for use in 
a competitive binding assay. Recognition of the gentamicin-bound complex by antisera to gentamicin was 
verified using a standard radioimmunoassay for gentamicin. 
Keywords: Fluorescence immunoassa y; gentamicin assay; terbium - transferrin label 
The last decade has seen several attempts to develop 
non-isotopic immunoassays with a view to replacing radioim- 
munoassay methods which have many well documented 
disadvantages. 
Several approaches have been made to the use of metal ions 
as labels in immunoassay: CaislJ used derivatives of sandwich 
compounds such as ferrocene to label steroids and other 
molecules, detection of the labelled species being carried out 
by atomic-absorption spectrometry. These labels were rela- 
tively insensitive in immunoassays, no doubt partly because 
the metals used (Fe, Mn, etc.) occur at high concentrations in 
biological samples. Cais subsequently synthesised metallo- 
haptens by the mercuration of steroid estrogens,3 where the 
metal atoms were introduced directly into the molecule of the 
antigen, and by the formation of cymatrene complexes 
containing manganese.4 Leuvering et al.5 have studied the use 
of colloidal coating with atomic-absorption spectrometric 
determination. 
In this paper we report the potential use of lanthanide ions 
as labels in immunoassay. In principle, lanthanide ion 
complexes should form useful labels in immunoassay as they 
are highly fluorescent and the concentration of lanthanide ions 
in biological samples is extremely low. In particular, a study 
has been made of the potential of the complex between 
terbium and transferrin as a label in the immunoassay of 
gentamicin. 
Human serum transferrin has the function in the body of 
binding and transporting iron in the plasma in the form of 
Fe3+. Transferrin binds two iron(II1) ions per molecule in 
specific sites on the polypeptide chain, but in the absence of 
iron these sites may be occupied by lanthanide ions to form 
highly fluorescent complexes. 
Gentamicin is an aminoglycosidic antibiotic used in the 
treatment of severe Gram-negative bacteria. Its optimum 
therapeutic concentration in human serum is 4-12 mg 1-1 
(9-20 pmol I - l ) ,  maintained by intramuscular injection: 
0.8 mg per kilogram body mass every 8 h. It is extremely 
effective but has a low therapeutic ratio and therefore its level 
must be monitored by a simple, rapid and reliable method. 
Experimental 
Apparatus 
All fluorescence spectra were measured on a Perkin-Elmer 
Model LS-5 luminescence spectrometer fitted with an R928 
photomultiplier. Data were recorded using a Perkin-Elmer 
Model 3600 data station using PECLS I1 applications soft- 
ware, which permitted the calculation of corrected spectra and 
phosphorescence lifetimes. 
Reagents 
Terbium chloride and glycine were obtained from Aldrich 
Chemical Co. and iron-free transferrin, gentamicin sulphate 
and l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydro- 
chloride from Sigma London Chemical Co. 
All radioimmunoassays were carried out using a radioim- 
munoassay kit supplied by RIA (UK) Ltd. 
Antibodies used in the antibody binding experiments were 
supplied by Sigma Chemical Co. Ltd. 
Fluorescence of Terbium and the Terbium - Transferrin 
Complex 
Fluorescence spectra of terbium chloride in aqueous solution 
and a terbium - transferrin complex in Tris - hydrochloric acid - 
hydrogen carbonate buffer6 were recorded. 
The limits of detection of the complex and its fluorescence 
lifetime (the time for the fluorescence of a sample to decay to 
the background level) were also determined. 
The complex for the above experiments was prepared by the 
addition of aqueous terbium chloride to iron-free transferrin 
in Tris - hydrochloric acid - hydrogen carbonate buffer in the 
molar ratio 2 : 1. 
Linkage of Gentamicin to Transferrin 
The linkage of gentamicin to transferrin was achieved using a 
carbodiimide reagent. In this procedure a free acid group on 
the transferrin molecule is linked to a free amino group on the 
gentamicin. Experiments were carried out using 1-ethyl-3-(3- 
dimethylaminopropy1)carbodiimide hydrochloride in aqueous 
solution. 
Iron-free transferrin (30 mg), gentamicin (60 mg) and the 
carbodiimide (400 mg) were incubated at room temperature in 
distilled water (2.5 ml) for varying lengths of time before 
separation of the protein fraction on a Sephadex G-25 column 
by elution with Tris - hydrochloric acid - hydrogen carbonate 
buffer (pH 8.5). Verification of gentamicin binding was 
carried out using 125I-labelled gentamicin. 
The carbodiimide procedure was repeated using various 
glycine to gentamicin ratios for the gentamicin in the original 
experiment, the reaction time being 5 min in each instance. 
The reaction products were subsequently analysed for their 
gentamicin content by radioimmunoassay and their fluores- 
cence was measured after terbium binding. 
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Fig. 1. Emission spectra of terbium chloride and a terbium -
transferrin complex. l, 10-5 M terbium - transferrin compl ex; and 2,
100 mM terbium chloride 
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I:ig. 2. Emission spectra of 1 : 100 human serum with various delay 
times: l, 0.01; 2, 0.02; and 3, 0.05 ms 
Titration of the Gentamicin - Glycine Bound Complex against 
Anti-gentamicin 
The effect on the fluorescence of the complex in various 
concentrations of antiserum to gentarnicin (raised in rabbit) 
was investigated using the double antibody technique with 
anti-rabbit IgG. Fluorescence measurements were taken 
following incubation, precipitation and centrifugation. 
Results and Discussion 
Fluorescence of Terbium and the Terbium · Transferrin 
Complex 
Fig. 1 shows an enhancement of the fluorescence intensity of 
terbium of the order of 105 when the complex is excited at 295 
nm. This fluorescence enhancement is due to an intramole­
cular energy transfer process within the complex. This is 
demonstrated by the fact that the complex excitation is in the 
region of the ligand absorbing region whereas the emission is 
typical of the "line" emission of the terbium ion. 
The limit of detection of the complex was shown to be 10-7 
M with respect to transferrin, a result which suggests that the 
complex has a suitable fluorescence intensity for use as a label 
in the analysis of drugs by immunoassay. 
The complex had a lifetime of 1.25 ms. Subsequent delayed 
fluorescence experiments (Fig. 2) showed that interference 
due to scattered light from blood serum could be reduced to 
zero with a delay gate of 0.05 ms. The subsequent decrease in 
fluorescence intensity of the complex was l�ss than 5%. The 
following instrumental conditions were thus chosen: excita­
tion slit, 5.0 nm; emission slit, 5.0 nm; excitation wavelength, 
295 nm; delay time, 0.05 ms; gate time, 5.0 ms; and fixed-scale 
mode. 
Table 1. Results of analysis of complex for gentamicin by 
radioimmunoassay 
Analyte 
0 µg ml- 1 standard 
1 µgml- 1 standard 
2 µg ml-1 standard
4 µgml - 1 standard 
8 µg ml-1 standard
16µgml-1 standard
Glycine : gentamicin rati� 
0:20 
2: 18 
5: 15 
10: 10 
15:5 
18:2 
C.p .s.
42 039 
36 557 
28 737 
16 771 
9 860 
6 481 
1 023 j
540 
1 073 
1870 
7 497 
11 493 
Gentamicin 
determin ed/ 
µgm1-1 
>16
8-16
4-8
Table 2. Results of stability tests on the glycine - gentamicin bound 
complex 
Fluorescence Fluorescence 
Time after intensity in intensity in 
formation buffer 1: lOOserum 
Omin 104.95 64.19 
5min 109.55 67.48 
lOmin 103.50 71. 19
15min 104.25 72.84
30min 107.10 74.07
45min 106.20 74.80
lh 107.05 77.45
24h 109.00 77.46
7d 110.95 77.46
Linkage of Gentamicin to Transferrin 
The experiments carried out using 12s1.1abelled gentamicin 
showed that with reaction times from 5 min to 1 h substantial 
gentamicin binding was occurring. 
Analysis of the Gentamicin Content of Complexes with 
Substituted Glycine 
Table 1 shows the amount of gentamicin bound per millilitre 
of solution for various reaction mixtures as analysed by 
standard radioimmunoassay for gentamicin. 
It can be seen that gentamicin - glycine bound complexes 
with glycine to gentamicin ratios of less than 15 : 5 have too 
high a gentamicin content for use in a competitive binding 
assay for the therapeutic blood concentration range of 
gentamicin (4--12 µg ml-1). 
Fluorescence measurements on the complexes modified by 
glycine and gentamicin showed a decrease in fluorescence 
intensity of less than 5% compared with the original terbium -
transferrin complex. 
Stability of the Gentamicin - Glycine Bound Complex 
It can be seen from Table 2 that a complex containing a glycine 
to gentamicin ratio of 9 : 1 is stable in buffer and buffer 
containing 1 : 100 human serum over a period of at least 7 d. 
Absorbance measurements at 295 nm showed that the 
decrease in fluorescence intensity in 1 : 100 serum was due to 
the increased absorbance of the solution at that wavelength. 
Titration of the Glycine - Gentamicin Complex against 
Anti-gentamicin 
Titration of the complex against anti-gentamicin (Fig. 3) 
shows good antibody recognition of the complex, the curve 
shape being typical of such a dilution analysis. 
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Fig. 3. Antibody dilution analysis of the terbium transfcrrin 
gentamicin - glycine complex 
Conclusion 
The results suggest that a glycine - gentamicin bound terbium -
transferrin complex has potential as a non-isotopic immunoas­
say label. However, it is felt that careful consideration should 
be given to the final format of the immunoassay, owing to 
possible effects of the macromolecular label. At present the 
most suitable separation methods are being established. 
Although the terbium - transferrin complex shows potential 
as an alternative label in immunoassay, it has the disadvantage 
of sensitivity suitable only for the detection of drugs and not 
hormones. One means of increasing the sensitivity is to 
increase the fluorescence intensity. Further study of the 
intramolecular energy transfer process7 -8 such as are involved 
in the terbium - transferrin complex might prove useful in this 
respect. The bifunctional reagents that would be suitable are 
of the type described by Meares and co-workers,9 11J which 
have "EDT A" groups and groups suitable for binding to 
amino acids at opposite extremities of the molecule. Another 
alternative is the use of bifunctional reagents where the 
chelating agent is "iminodiacetic acid. "11 12 
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